Open AccessHighly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau
Author(s) -
Rosenqvist Nina,
Asuni Ayodeji A.,
Andersson Christian R.,
Christensen Søren,
Daechsel Justus A.,
Egebjerg Jan,
Falsig Jeppe,
Helboe Lone,
Jul Pia,
Kartberg Fredrik,
Pedersen Lars Ø.,
Sigurdsson Einar M.,
Sotty Florence,
Skjødt Karsten,
Stavenhagen Jeffrey B.,
Volbracht Christiane,
Pedersen Jan T.
Publication year - 2018
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2018.09.005
Subject(s) - seeding , antibody , chemistry , biology , genetics , agronomy
The abnormal hyperphosphorylation of the microtubule‐associated protein tau plays a crucial role in neurodegeneration in Alzheimer's disease (AD) and other tauopathies. Methods Highly specific and selective anti‐pS396‐tau antibodies have been generated using peptide immunization with screening against pathologic hyperphosphorylated tau from rTg4510 mouse and AD brains and selection in in vitro and in vivo tau seeding assays. Results The antibody C10.2 bound specifically to pS396‐tau with an IC 50 of 104 pM and detected preferentially hyperphosphorylated tau aggregates from AD brain with an IC 50 of 1.2 nM. C10.2 significantly reduced tau seeding of P301L human tau in HEK293 cells, murine cortical neurons, and mice. AD brain extracts depleted with C10.2 were not able to seed tau in vitro and in vivo, demonstrating that C10.2 specifically recognized pathologic seeding‐competent tau. Discussion Targeting pS396‐tau with an antibody like C10.2 may provide therapeutic benefit in AD and other tauopathies.